sepsis causing News
-
World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.
Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians Declared a Global Health Priority by the World Health Organization in 2017 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment Vancouver, Canada: Noting World Sepsis ...
-
CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic
Marking “World Sepsis Day”, The Centre for Drug Research and Development (CDRD) announces the spin-off of a new company, Sepset Biosciences Inc. The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims ...
-
Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals Joins ExThera Medical Board of Directors
Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company Dr. Chawla is an internationally renowned ...
-
Inflammatix Announces $32 Million in Series C Funding
Financing will be used to advance HostDx tests for acute infections and sepsis to commercial launch in 2021. Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced a $32 million Series C financing. The funding round included participation from existing investors Khosla Ventures, Northpond Ventures and Think.Health Ventures, and ...
-
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF ...
-
Environmental Surface Cleaning and Disinfecting for MRSA in the General Community Discussed in New Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses Methicillin-resistant Staphylococcus aureus (MRSA) and information provided by the Centers for Disease Control and Prevention (CDC) about environmental surface cleaning and disinfecting. “MRSA is a type of staph bacteria that is resistant ...
-
Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. Sepsis is the body’s overwhelming and life-threatening ...
-
Abionic: International Pivotal Study Successfully Demonstrates Diagnosis of Sepsis within 5 Minutes – 24 Hours Earlier Compared with Current Standard-of-Care
Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful completion of its multi-center observational study using Abionic’s novel point-of-care Pancreatic Stone Protein (PSP) sepsis test on the abioSCOPE® platform. The results of the study show an anticipation of 24 hours for the diagnosis of sepsis compared to current ...
By Abionic SA
-
Notitia Biotechnologies company announces expansion of study population for Covid-19 phase 2 study (COVGUT20) for NBT-NM108
After months of preparation, Notitia Biotechnologies Company (Notitia) announced that its COVID-19 Phase 2 study (COVGUT20) for NBT-NM108 has been given support by the Food and Drug Administration (FDA) to expand its study population to all symptomatic COVID-19 patients. "Previously, our trial focused on COVID-19 patients with type 2 diabetes and prediabetes. Now with this timely expansion to ...
-
Rutgers researcher invents Microbiota Formula to help high-risk patients fight Covid-19
A Rutgers scientist has invented an early treatment for COVID-19 to prevent severe complications and hospitalizations in patients with prediabetes and diabetes by increasing beneficial bacteria in the gut and reducing organisms that cause coronavirus. The treatment – created by researcher Liping Zhao – was given the Investigational New Drug status by the Food and Drug ...
-
Cytovale Receives Distinguished Abstract Award from AACC for Evaluation of Sepsis Assay
Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, has received an AACC Academy’s Distinguished Abstract Award for its abstract titled “Rapidly Assessing the Host Immune Response for the Diagnosis of Sepsis, a Prospective Multi-Site Clinical Study in the Emergency Department (ED) Employing the Leukocyte ...
-
Magnolia Medical Appoints Industry Veteran, Joseph Bishop, as the Senior Vice President of Operations and Product Development
Magnolia Medical Technologies, Inc., inventors of Steripath, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the addition of Joseph Bishop to the executive leadership team as Senior Vice President of Operations and Product Development. Mr. Bishop brings extensive and diverse medical device experience to Magnolia ...
-
Magnolia Medical Announces Expansion of Its Extensive Clinical Evidence Library with Six Steripath® ISDD® Studies in 2021 Demonstrating Zero or Near-Zero False Positive Sepsis Test Results
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced that six studies, reporting zero or near-zero blood culture contamination rates and up to a 31% reduction in vancomycin days of therapy (DOT) using Steripath, were submitted, accepted and published in ...
-
Magnolia Medical Further Strengthens Executive Management Team with the Addition of Silicon Valley Financial Leader, Patrick O’Malley, as Chief Financial Officer
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the expansion of its senior leadership team with the addition of Patrick O’Malley as Chief Financial Officer. Mr. O’Malley is a seasoned public company executive bringing over three decades ...
-
Magnolia Medical, MHA Solutions, and Healthcare Providers Insurance Company Enter into an Exclusive, Endorsed Agreement for the Steripath Initial Specimen Diversion Device
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC), a reciprocal insurer that ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you